17737-65-4
Chemical Structure
Clonixin
Synonym(s): SCH-10304
- CAS No.: 17737-65-4
- Formula:C13H11ClN2O2
- Molecular Weight:262.69
IUPAC Name: 2-((3-chloro-2-methylphenyl)amino)nicotinic acid
InChIKey: CLOMYZFHNHFSIQ-UHFFFAOYSA-N
SMILES: O=C(C1=CC=CN=C1NC2=CC=CC(Cl)=C2C)O
Biological Activity: Clonixin (SCH-10304) is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca2+ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Clonixin | 98.88% | Clonixin (SCH-10304) is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca2+ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Clonixin (Standard) | ≥98% | Clonixin (SCH-10304) (Standard) is the analytical standard of Clonixin. This product is intended for research and analytical applications. Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca2+ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Clonixin-13C,d3 | Clonixin-13C,d3 (SCH-10304-13C,d3) is the deuterium and 13C-labeled Clonixin (HY-121235). Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca2+ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Gawli C, et al. Repurposing clonixin and flunixin as anti-fibrotic candidates: Computational and preclinical evaluation in bleomycin-induced pulmonary fibrosis in rats. Res Vet Sci. 2025 Dec;197:105923.
[Content Brief] -
[2]. Ferreira H, et al. Interaction of clonixin with EPC liposomes used as membrane models. J Pharm Sci. 2005 Jun;94(6):1277-87.
[Content Brief] -
[3]. Bustamante D, et al. Analgesic action of clonixin, nifedipine and morphine using the formalin test. Gen Pharmacol. 1989;20(3):319-22.
[Content Brief] -
[4]. Morales MA, et al. Vasorelaxant effect of the analgesic clonixin on rat aorta. Gen Pharmacol. 1995 Mar;26(2):425-30.
[Content Brief]
